ETF Holdings Breakdown of YMAB

News associated with YMAB

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Short Interest Update

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) saw a significant decrease in short interest in the month of April. As of April 15th, there was short interest totalling 3,070,000 shares, a decrease of 16.1% from the March 31st total of 3,660,000 shares. Based on an average daily volume of 400,200 shares, the short-interest ratio […] - 2025-05-05 05:35:05

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $18.30 Consensus Target Price from Brokerages

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) have been given a consensus rating of “Moderate Buy” by the eleven brokerages that are presently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, seven have issued a buy rating and two have given a strong buy rating […] - 2025-04-23 05:46:51

32,256 Shares in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Purchased by ExodusPoint Capital Management LP

ExodusPoint Capital Management LP bought a new stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Free Report) during the fourth quarter, HoldingsChannel reports. The fund bought 32,256 shares of the company’s stock, valued at approximately $253,000. Several other hedge funds and other institutional investors also recently bought and sold shares of YMAB. State Street Corp grew […] - 2025-04-14 07:46:52

Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Cut to $18.00 by Analysts at Truist Financial

Y-mAbs Therapeutics (NASDAQ:YMAB – Get Free Report) had its target price decreased by analysts at Truist Financial from $21.00 to $18.00 in a report released on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Truist Financial’s target price indicates a potential upside of 242.86% from the company’s previous close. YMAB has […] - 2025-03-07 06:30:47

Brokerages Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Target Price at $20.89

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) have received an average recommendation of “Buy” from the ten brokerages that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and two have given a strong buy rating […] - 2025-03-04 06:35:15

Brokerages Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Price Target at $20.89

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) have earned a consensus rating of “Buy” from the ten ratings firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have issued a strong buy rating on […] - 2025-02-07 06:49:03

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Position Boosted by JPMorgan Chase & Co.

JPMorgan Chase & Co. lifted its stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Free Report) by 10.4% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 30,335 shares of the company’s stock after purchasing an additional 2,854 shares during the quarter. JPMorgan Chase […] - 2025-01-30 08:59:08

YMAB institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-02-27	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	9,153	USD 49,609 -1.7%
2025-05-08	IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc))	48,126	USD 194,429 4.0%
2025-05-08	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	19,643	USD 79,358
2025-05-08	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	19,643	USD 79,358 4.0%
Total =		96,565	USD 402,754

Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer